Adaptive Biotechnologies (ADPT) Research & Development (2018 - 2025)
Adaptive Biotechnologies (ADPT) has disclosed Research & Development for 8 consecutive years, with $21.8 million as the latest value for Q4 2025.
- Quarterly Research & Development fell 6.16% to $21.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.8 million through Dec 2025, down 8.92% year-over-year, with the annual reading at $93.8 million for FY2025, 8.92% down from the prior year.
- Research & Development hit $21.8 million in Q4 2025 for Adaptive Biotechnologies, down from $23.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $37.8 million in Q1 2022 to a low of $21.8 million in Q4 2025.
- Historically, Research & Development has averaged $30.1 million across 5 years, with a median of $30.7 million in 2022.
- Biggest five-year swings in Research & Development: surged 45.43% in 2021 and later fell 21.35% in 2024.
- Year by year, Research & Development stood at $34.7 million in 2021, then fell by 10.02% to $31.2 million in 2022, then decreased by 7.93% to $28.7 million in 2023, then fell by 19.32% to $23.2 million in 2024, then fell by 6.16% to $21.8 million in 2025.
- Business Quant data shows Research & Development for ADPT at $21.8 million in Q4 2025, $23.7 million in Q3 2025, and $24.1 million in Q2 2025.